

November 8, 2010
FOR IMMEDIATE RELEASE

Ei Yamada, President and CEO
AnGes MG, Inc.
(Code No. 4563, TSE Mothers)
Contact: Fumihiko Suzuki, Director, Corporate Planning Dept.
Tel: +81-3-5730-2480

Angiogenic Therapy with Collatogene™ (HGF gene therapy product), a Therapeutic Agent for Ischemic Diseases, Adopted as Grant Project by the U.S. Department of the Treasury

AnGes MG, Inc. announced today that AnGes, Inc., the U.S. subsidiary of AnGes MG, has been awarded a grant for the angiogenic therapy utilizing the therapeutic agent for ischemic diseases Collatogene™ under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP).

The QTDP was established in March 2010 by Congress, as enacted under the Patient Protection and Affordable Care Act, and provides a tax credit or grant equal to 50% of eligible costs and expenses for the tax years of 2009 and 2010. This program was designed to promote small-scale companies to support their developments in innovative therapies for unmet medical needs that could prevent, diagnose and treat acute and chronic diseases, that showed significant potential to produce new and cost-saving therapies, support employment and increase U.S. competitiveness.

Regarding this adoption, Ei Yamada, AnGes MG's President & CEO commented, "The fact that angiogenic therapy with Collatogene™ was selected for grants under the QTDP program in the United States where the number of patients suffering from critical limb ischemia is overwhelmingly larger compared to Japan and other Asian countries, means that the healthcare as well as social significance of Collatogene™ has been recognized by the U.S. government and also that there are very high expectations for Collatogene™. And this obliges us to promptly achieve the introduction of Collatogene™ into the market."

The effect of this trend on AnGes MG's business performance for the term ending in December 2010 is currently being calculated, and it will be published as soon as the results become clear.

###